Comparison · NCT00004635-51957644
Thalidomide vs Placebo: The Number of Participants With Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Thalidomide vs Placebo: The Number of Participants With Adverse Events. Trial comparisons, record NCT00004635-51957644. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00004635-51957644
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.848 | 0.779 | 0.898 | wilson | |
| Risk in group 2 | 0.79 | 0.71 | 0.853 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0575 | -0.0357 | 0.152 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.956 | 1.2 | log | |
| Odds ratio, group 1 over group 2 | 1.48 | 0.784 | 2.79 | log | |
| Number needed to treat, for one more participant with the outcome on Thalidomide than on Placebo | 17.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Thalidomide | Participants who received thalidomide in period 1 or 2. | 117 | 138 | OG000 |
| Group 2 | Placebo | Participants who received placebo in period 1 or 2. | 98 | 124 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number of Participants With Adverse Events
- Description
- Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
- Time frame
- Date treatment consent signed to date off study, approximately 60 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- NCT number
- NCT00004635
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- Thalidomide, leuprolide acetate, goserelin, Placebo
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2012-09-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00004635?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00004635-51957644